SGLT2 inhibitor for secondary prevention in acute myocardial infarction patients with diabetes mellitus

被引：0
|
作者：
Kim, D. B. [1 ]
Kim, H. Y. [1 ]
机构：
[1] Catholic Univ Korea, Seoul, South Korea
来源：
EUROPEAN HEART JOURNAL | 2023年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] SGLT2 Inhibition in Acute Myocardial Infarction-A Comprehensive Review
    Benedikt, Martin
    Kolesnik, Ewald
    Sourij, Harald
    von Lewinski, Dirk
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2023, 24 (02)
  • [22] SGLT2 Inhibitors: New Hope for the Treatment of Acute Myocardial Infarction?
    Wu, Yu-Jie
    Wang, Si-Bo
    Wang, Lian-Sheng
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2022, 22 (06) : 601 - 613
  • [23] Should All Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease Receive an SGLT2 Inhibitor?
    Barry, Arden R.
    Mitchelmore, Bradley R.
    CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2018, 71 (04): : 282 - 285
  • [24] SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart
    Lim, Ven G.
    Bell, Robert M.
    Arjun, Sapna
    Kolatsi-Joannou, Maria
    Long, David A.
    Yellon, Derek M.
    JACC-BASIC TO TRANSLATIONAL SCIENCE, 2019, 4 (01): : 15 - 26
  • [25] Influence of the SGLT2 inhibitor empagliflozin on post myocardial infarction rat hearts
    Damatto, F. C.
    Paschoareli, G. L.
    Rosa, C. M.
    Gomes, M. J.
    Pagan, L. U.
    Damatto, R. L.
    Rodrigues, E. A.
    Pontes, T. H.
    Reyes, D. R. A.
    Cezar, M. D. M.
    Oliveira, L. R. S.
    Zornoff, L. A. M.
    Rego, A. B. G. C.
    Okoshi, M. P.
    Okoshi, K.
    EUROPEAN HEART JOURNAL, 2022, 43 : 1115 - 1115
  • [26] Use of secondary prevention pharmacotherapy after first myocardial infarction in patients with diabetes mellitus
    Casper H Jørgensen
    Gunnar H Gislason
    Ole Ahlehoff
    Charlotte Andersson
    Christian Torp-Pedersen
    Peter R Hansen
    BMC Cardiovascular Disorders, 14
  • [27] Use of secondary prevention pharmacotherapy after first myocardial infarction in patients with diabetes mellitus
    Jorgensen, Casper H.
    Gislason, Gunnar H.
    Ahlehoff, Ole
    Andersson, Charlotte
    Torp-Pedersen, Christian
    Hansen, Peter R.
    BMC CARDIOVASCULAR DISORDERS, 2014, 14
  • [28] Association of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Use With Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Patients With Stabilized Acute Myocardial Infarction: A Propensity Score Matching Study
    Chang, Ting-Yung
    Lu, Chi-Ting
    Huang, Hsin-Lei
    Chou, Ruey-Hsing
    Chang, Chun-Chin
    Liu, Chung-Te
    Huang, Po-Hsun
    Lin, Shing-Jong
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [29] Letter to the Editor Regarding “The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus”
    Yafei Xie
    Xiaowei Zhang
    Cardiovascular Drugs and Therapy, 2022, 36 : 571 - 572
  • [30] Letter to the Editor Regarding "The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus"
    Xie, Yafei
    Zhang, Xiaowei
    CARDIOVASCULAR DRUGS AND THERAPY, 2022, 36 (03) : 571 - 572
12345